XENE - Company ID 0001582313
Xenon Pharmaceuticals Inc. trades as XENE and has a market capitalization of $6.70 B, making it the #1201 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $7.50M and net income of -$345.91M. This page tracks Xenon Pharmaceuticals Inc. through 761 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 10 fiscal years Xenon Pharmaceuticals Inc.'s revenue declined from $15.58M to $7.50M, a compound annual decline rate of 7.0%. Net profit margin compressed from -1275.5% to -4612.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-22 |
| Proxy materials | DEFA14A | 2026-04-22 |
| Proxy statement | DEF 14A | 2026-04-22 |
Xenon Reports Q1 2026 Financial Results and Provides Business Update | Xenon Pharmaceuticals Inc.
(800) 715-9871 toll-free or (646) 307-1963 for international callers
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Xenon Pharmaceuticals Inc.
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting | Xenon Pharmaceuticals Inc.
Xenon to Present at Upcoming Investor Conferences | Xenon Pharmaceuticals Inc.
The largest companies sharing Xenon Pharmaceuticals Inc.'s SEC industry classification (pharmaceutical preparations).
Xenon Pharmaceuticals Inc. (XENE) has a market capitalization of $6.70 B as of 2026-07-09, ranking #1201 among US-listed companies.
Xenon Pharmaceuticals Inc. reported revenue of $7.50M for fiscal year 2025.
In its latest fiscal year Xenon Pharmaceuticals Inc. reported a net loss of $345.91M.